[Diabetes mellitus and the female reproductive system tumors].


Journal

Problemy endokrinologii
ISSN: 2308-1430
Titre abrégé: Probl Endokrinol (Mosk)
Pays: Russia (Federation)
ID NLM: 0140673

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 19 03 2023
accepted: 11 05 2023
revised: 19 04 2023
medline: 17 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

The article discusses various pathophysiological conditions and processes that lead to the development of tumors in diabetes mellitus. These include obesity, hyperglycemia, hyperinsulinemia, inflammation, and oxidative stress. The data of epidemiological studies are given, in which it was found that diabetes mellitus (both type 1 and type 2) increases the risk of developing the female reproductive system tumors, such as ovarian cancer, endometrial cancer, while for cervical cancer, vaginal cancer and vulvar cancer, such a relationship has not been clearly identified.

Identifiants

pubmed: 37448252
doi: 10.14341/probl13282
pmc: PMC10350608
doi:

Types de publication

English Abstract Journal Article

Langues

rus

Sous-ensembles de citation

IM

Pagination

103-110

Références

J Clin Invest. 2007 May;117(5):1175-83
pubmed: 17476347
Surg Today. 2017 Feb;47(2):151-158
pubmed: 27061803
Arch Physiol Biochem. 2008 Feb;114(1):23-37
pubmed: 18465356
Cells. 2020 Jun 02;9(6):
pubmed: 32498358
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Gynecol Oncol. 2014 Nov;135(2):273-7
pubmed: 25220626
Diabetes Metab J. 2019 Dec;43(6):733-743
pubmed: 31902143
BMC Cancer. 2019 May 31;19(1):527
pubmed: 31151429
Front Oncol. 2022 Jul 18;12:883805
pubmed: 35924174
Biomed Res Int. 2015;2015:538019
pubmed: 25866791
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
J Oncol. 2010;2010:514310
pubmed: 20182531
J Hyg (Lond). 1914 Apr;14(1):83-118
pubmed: 20474569
Int J Cell Biol. 2012;2012:762825
pubmed: 22666258
Int J Cancer. 2004 Mar;109(1):149-52
pubmed: 14735482
Probl Endokrinol (Mosk). 2021 Sep 10;67(5):34-42
pubmed: 34766488
Discov Med. 2015 Sep;20(109):121-8
pubmed: 26463093
Endocr Relat Cancer. 2012 Nov 09;19(6):R225-41
pubmed: 22936542
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
J Cancer Metastasis Treat. 2017;3:45-59
pubmed: 28626800
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Acta Pharmacol Sin. 2008 Nov;29(11):1275-88
pubmed: 18954521
Diabetes Metab Res Rev. 2017 May;33(4):
pubmed: 27860198
Diabetes Res Clin Pract. 2018 Sep;143:378-388
pubmed: 29679627
Cancers (Basel). 2020 May 08;12(5):
pubmed: 32397158
Curr Pharm Des. 2008;14(10):940-5
pubmed: 18473843
Endocrinol Metab Clin North Am. 2020 Jun;49(2):239-250
pubmed: 32418587
Physiol Rev. 2015 Jul;95(3):727-48
pubmed: 26084689
Clin Chem Lab Med. 2018 Aug 28;56(9):1413-1425
pubmed: 29427549
Expert Rev Endocrinol Metab. 2010 Jan 1;5(1):19-28
pubmed: 20204165
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
PLoS One. 2011;6(11):e27074
pubmed: 22087246
Cancer Sci. 2012 Jul;103(7):1201-6
pubmed: 22469133
J Exp Med. 2012 Aug 27;209(9):1689-702
pubmed: 22908325
PLoS One. 2021 Mar 9;16(3):e0248103
pubmed: 33690729
Diabetologia. 2016 May;59(5):980-8
pubmed: 26924393
Diabetologia. 2017 Jun;60(6):1022-1032
pubmed: 28265721
World J Diabetes. 2011 Jul 15;2(7):108-13
pubmed: 21860695
Int J Hyperthermia. 2013 Aug;29(5):464-73
pubmed: 23862980
Int J Cancer. 2015 Aug 15;137(4):903-10
pubmed: 25604005
Diabetologia. 2007 Jul;50(7):1365-74
pubmed: 17476474
BMC Cancer. 2022 Apr 20;22(1):427
pubmed: 35439978
J Transl Med. 2009 Mar 17;7:17
pubmed: 19292913
Int J Gynecol Cancer. 2013 Mar;23(3):402-12
pubmed: 23354371
Medicine (Baltimore). 2017 Oct;96(40):e7981
pubmed: 28984757
Gynecol Oncol. 2015 Nov;139(2):319-23
pubmed: 26360017
Diabetes Care. 2020 Sep;43(9):2313-2322
pubmed: 32910779
BMJ Open. 2020 Dec 29;10(12):e040137
pubmed: 33376163
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7623-7628
pubmed: 28667123
Mol Diagn Ther. 2014 Apr;18(2):137-51
pubmed: 24403167
Obes Surg. 2019 Mar;29(3):1031-1039
pubmed: 30591985
Front Endocrinol (Lausanne). 2022 Oct 27;13:993785
pubmed: 36387876
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Pathol Oncol Res. 2020 Jul;26(3):1377-1384
pubmed: 31203571
Obes Rev. 2021 Dec;22(12):e13337
pubmed: 34476900
Clin Diabetes. 2020 Jul;38(3):256-265
pubmed: 32699474
BMC Cancer. 2018 Jul 28;18(1):767
pubmed: 30055585

Auteurs

K I Sharafutdinova (KI)

First Moscow State Medical University (Sechenov University).

V S Shlyapina (VS)

Russian National Research Medical University named after N.I. Pirogov.

A I Baeva (AI)

Russian National Research Medical University named after N.I. Pirogov.

A A Timurshin (AA)

Bashkir State Medical University.

I E Sabanaeva (IE)

Bashkir State Medical University.

A G Nakieva (AG)

Bashkir State Medical University.

M F Kalashnikova (MF)

First Moscow State Medical University (Sechenov University).

M N Khabibov (MN)

First Moscow State Medical University (Sechenov University).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH